Cannapharmarx Financials
This page shows Cannapharmarx (CPMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
For every $1 of reported earnings, Cannapharmarx generates $0.07 in operating cash flow (-$789K OCF vs -$11.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Cannapharmarx earns $-1.7 in operating income for every $1 of interest expense (-$3.3M vs $2.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Cannapharmarx generated $1.4M in revenue in fiscal year 2025. This represents an increase of 66.1% from the prior year.
Cannapharmarx reported -$11.1M in net income in fiscal year 2025. This represents a decrease of 12.4% from the prior year.
Cannapharmarx earned $-0.02 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Cash & Balance Sheet
Cannapharmarx generated -$795K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 53.2% from the prior year.
Cannapharmarx had 679M shares outstanding in fiscal year 2025. This represents an increase of 2.4% from the prior year.
Margins & Returns
Cannapharmarx's gross margin was -153.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 204.8 percentage points from the prior year.
Cannapharmarx's operating margin was -245.8% in fiscal year 2025, reflecting core business profitability. This is up 193.9 percentage points from the prior year.
Cannapharmarx's net profit margin was -817.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 390.6 percentage points from the prior year.
Capital Allocation
Cannapharmarx spent $350K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Cannapharmarx invested $6K in capex in fiscal year 2025, funding long-term assets and infrastructure.
CPMD Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $657K+183.5% | $232K-30.9% | $335K | N/A | $312K | $0-100.0% | $26K | N/A |
| Cost of Revenue | $1.1M+28.6% | $853K+1.8% | $838K | N/A | $668K+290.0% | $171K-63.0% | $463K | N/A |
| Gross Profit | -$440K+29.2% | -$621K-23.6% | -$503K | N/A | -$356K-107.8% | -$171K+60.8% | -$437K | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $145K+91.5% | $76K+174.1% | $28K | N/A | $51K+847.7% | $5K-97.4% | $209K | N/A |
| Operating Income | -$936K-11.3% | -$841K-26.0% | -$668K | N/A | -$516K+0.4% | -$518K+34.5% | -$790K | N/A |
| Interest Expense | $506K-23.0% | $658K+6.8% | $616K | N/A | $632K-13.9% | $734K+27.3% | $576K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.5M-4.6% | -$1.4M-104.7% | -$691K+81.5% | -$3.7M-2085.4% | $188K-96.5% | $5.4M+145.8% | -$11.7M | N/A |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | N/A | $0.00-100.0% | $0.01+133.3% | $-0.03 | N/A |
CPMD Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.6M+1.3% | $11.5M+2.1% | $11.2M+3.7% | $10.8M-7.2% | $11.7M | N/A | $11.4M-3.2% | $11.7M |
| Current Assets | $1.5M+22.8% | $1.2M-3.1% | $1.2M+21.4% | $1.0M-32.0% | $1.5M | N/A | $1.0M-12.4% | $1.2M |
| Cash & Equivalents | $927-94.5% | $17K+1305.2% | $1K-44.0% | $2K-69.2% | $7K-23.5% | $9K-24.4% | $12K+1760.5% | $650 |
| Inventory | $864K-17.2% | $1.0M+9.7% | $951K-4.5% | $996K-18.3% | $1.2M | N/A | $950K-16.2% | $1.1M |
| Accounts Receivable | $588K+414.7% | $114K-56.5% | $263K+14947.3% | $2K-99.0% | $183K | N/A | $14K | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $34.1M+0.3% | $34.0M+7.3% | $31.7M+3.6% | $30.6M+8.4% | $28.3M | N/A | $34.9M+46.0% | $23.9M |
| Current Liabilities | $28.5M-1.6% | $29.0M+7.7% | $26.9M+4.4% | $25.8M+14.4% | $22.5M | N/A | $29.3M+56.2% | $18.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$22.5M+0.3% | -$22.6M-10.1% | -$20.5M-3.5% | -$19.8M-19.4% | -$16.6M+0.5% | -$16.7M+29.2% | -$23.5M-93.6% | -$12.2M |
| Retained Earnings | -$104.8M-1.4% | -$103.3M-1.4% | -$101.9M-0.7% | -$101.2M-3.8% | -$97.4M | N/A | -$103.0M-12.8% | -$91.3M |
CPMD Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$803K-79.8% | -$446K+25.8% | -$601K-234.3% | -$180K+66.7% | -$541K-26.5% | -$428K+22.1% | -$549K+57.9% | -$1.3M |
| Capital Expenditures | N/A | N/A | N/A | $0 | N/A | N/A | $0-100.0% | $2K |
| Free Cash Flow | N/A | N/A | N/A | -$180K | N/A | N/A | -$549K+58.0% | -$1.3M |
| Investing Cash Flow | N/A | N/A | N/A | $0 | N/A | N/A | $0+100.0% | -$2K |
| Financing Cash Flow | $787K+70.2% | $462K-23.0% | $600K+243.0% | $175K-67.5% | $539K+26.9% | $425K-24.2% | $560K-57.1% | $1.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CPMD Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -67.0%+201.2pp | -268.2%-118.3pp | -149.9% | N/A | -114.1% | N/A | -1692.8% | N/A |
| Operating Margin | -142.5%+220.6pp | -363.1%-164.0pp | -199.1% | N/A | -165.3% | N/A | -3058.1% | N/A |
| Net Margin | -225.1%+385.2pp | -610.3%-404.3pp | -205.9% | N/A | 60.4% | N/A | -45340.9% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -12.7%-0.4pp | -12.3%-6.2pp | -6.2%+28.4pp | -34.5%-36.1pp | 1.6% | N/A | -103.1% | N/A |
| Current Ratio | 0.05+0.0 | 0.040.0 | 0.050.0 | 0.04-0.0 | 0.07 | N/A | 0.04-0.0 | 0.06 |
| Debt-to-Equity | -1.520.0 | -1.51+0.0 | -1.550.0 | -1.55+0.2 | -1.70 | N/A | -1.48+0.5 | -1.97 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -2124.0% | N/A |
Similar Companies
Frequently Asked Questions
What is Cannapharmarx's annual revenue?
Cannapharmarx (CPMD) reported $1.4M in total revenue for fiscal year 2025. This represents a 66.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cannapharmarx's revenue growing?
Cannapharmarx (CPMD) revenue grew by 66.1% year-over-year, from $820K to $1.4M in fiscal year 2025.
Is Cannapharmarx profitable?
No, Cannapharmarx (CPMD) reported a net income of -$11.1M in fiscal year 2025, with a net profit margin of -817.2%.
What is Cannapharmarx's gross margin?
Cannapharmarx (CPMD) had a gross margin of -153.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cannapharmarx's operating margin?
Cannapharmarx (CPMD) had an operating margin of -245.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cannapharmarx's net profit margin?
Cannapharmarx (CPMD) had a net profit margin of -817.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cannapharmarx's free cash flow?
Cannapharmarx (CPMD) generated -$795K in free cash flow during fiscal year 2025. This represents a 53.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cannapharmarx's operating cash flow?
Cannapharmarx (CPMD) generated -$789K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cannapharmarx's capital expenditures?
Cannapharmarx (CPMD) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Are Cannapharmarx's earnings high quality?
Cannapharmarx (CPMD) has an earnings quality ratio of 0.07x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cannapharmarx cover its interest payments?
Cannapharmarx (CPMD) has an interest coverage ratio of -1.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.